DenosumabHypocalcaemia following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1808卷 / 1期

关键词：

D O I：

10.1007/s40278-020-79585-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：108 / 108

相关论文

共 50 条

[1] DenosumabHypocalcaemia following off-label use: case report
[J]. Reactions Weekly, 2022, 1923 (1) : 178 - 178
[2] DenosumabHypocalcaemia and rebound hypercalcaemia following off-label use: 4 case reports
[J]. Reactions Weekly, 2022, 1908 (1) : 200 - 200
[3] RituximabPancytopenia following off-label use: case report
[J]. Reactions Weekly, 2020, 1807 (1) : 176 - 176
[4] FavipiravirNephrotoxicity following off-label use: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 283 - 283
[5] DexamethasoneHyperglycaemia following off-label use: case report
[J]. Reactions Weekly, 2022, 1896 (1) : 173 - 173
[6] DexamfetamineHypertension following off-label use: case report
[J]. Reactions Weekly, 2021, 1883 (1) : 150 - 150
[7] NivolumabFever following off-label use: case report
[J]. Reactions Weekly, 2016, 1601 (1) : 186 - 186
[8] MirtazapineTachyphylaxis following off-label use: case report
[J]. Reactions Weekly, 2018, 1703 (1) : 182 - 182
[9] TocilizumabAnaphylaxis following off-label use: case report
[J]. Reactions Weekly, 2021, 1865 (1) : 397 - 397
[10] RivoceranibNeurotoxicity following an off-label use: case report
[J]. Reactions Weekly, 2018, 1702 (1) : 232 - 232

← 1 2 3 4 5 →